EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Han, SW
Jeong, S
Choi, IS
Kim, DN
Chung, DH
Im, SA
Kim, TY
Heo, DS
Bang, YJ
Kim, NK
机构：
[1] Seoul Natl Univ, Coll Med, Seoul, South Korea
[2] ISU ABXIS Inc, Seoul, South Korea
[3] Seoul Municipal Boramae Hosp, Seoul, South Korea
[4] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：639S / 639S
页数：1
相关论文
共 50 条
  • [1] EGFR, K-RAS and HER2 mutations as predictive factors for gefitinib sensitivity in non-small cell lung cancer (NSCLC)
    Voutsina, A.
    Kalikaki, A.
    Ampatziadis-Michailidis, Y.
    Souglakos, J.
    Koytsopoylos, A.
    Trypaki, M.
    Pallis, A.
    Stathopoylos, S.
    Mavroudis, D.
    Georgoulias, V.
    EJC SUPPLEMENTS, 2007, 5 (08): : 35 - 35
  • [2] K-ras mutations in non-small-cell lung carcinoma:: A review
    Aviel-Ronen, Sarit
    Blackhall, Fiona H.
    Shepherd, Frances A.
    Tsao, Ming-Sound
    CLINICAL LUNG CANCER, 2006, 8 (01) : 30 - 38
  • [3] Novel EGFR mutations in patients with non small cell lung cancer (NSCLC) and correlation T with sensitivity to gefitinib
    Voutsina, A.
    Koutsopoulos, A.
    Kalykaki, A.
    Souglakos, I.
    Pallis, A.
    Trypaki, M.
    Mavroudis, D.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2006, 17 : 250 - 251
  • [4] K-ras genotypes and prognosis in non-small-cell lung cancer
    Rosell, R
    Monzo, M
    Molina, F
    Martinez, E
    Pifarre, A
    Moreno, I
    Mate, JL
    deAnta, JM
    Sanchez, M
    Font, A
    ANNALS OF ONCOLOGY, 1995, 6 : 15 - 20
  • [5] Induced expression and activation of oncogenes in NSCLC (non-small cell lung cancer) in the absence of activating mutations of EGFR and k-Ras
    Gorgisen, Gokhan
    Ozes, Derya
    Pehlivanoglu, Suray
    Erdogan, Abdullah
    Dertsiz, Levent
    Ozbilim, Gulay
    Ozbudak, Irem Hicran
    Ozes, Osman N.
    CANCER RESEARCH, 2012, 72
  • [6] Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
    Garassino, M. C.
    Marabese, M.
    Rusconi, P.
    Rulli, E.
    Martelli, O.
    Farina, G.
    Scanni, A.
    Broggini, M.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 235 - U277
  • [7] Codon 12 K-ras mutations in plasma DNA are not an indicator of disease in non-small-cell lung cancer (NSCLC) patients.
    Betta, PG
    Trombino, S
    Angelini, C
    Neri, M
    Puntoni, R
    Filiberti, R
    Loprevite, M
    Orecchia, S
    Libener, R
    Russo, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 671S - 671S
  • [8] K-RAS ACTIVATION IN NON-SMALL-CELL LUNG-CANCER IN THE DOG
    KRAEGEL, SA
    GUMERLOCK, PH
    DUNGWORTH, DL
    OREFFO, VIC
    MADEWELL, BR
    CANCER RESEARCH, 1992, 52 (17) : 4724 - 4727
  • [9] EGFR and K-Ras Gene Mutations in the Diagnosis of Non-Small Cell Lung Cancer and their Pathological Correlation
    Wu, Zhenhua
    Yibulayin, Waresijiang
    He, Dan
    Xu, Keming
    Yibulayin, Xiayimaierdan
    Ma, Lei
    Sun, Xiaohong
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2024, 20 (05) : 874 - 882
  • [10] Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
    Park, In Hae
    Kim, Jin Young
    Jung, Jae In
    Han, Ji-Youn
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) : 791 - 799
12345